Rim Dhahri*, Selma Athimni, Maroua Slouma, Leila Metoui, Imene Gharsallah and Bassem Louzir Pages 1-4 (4)
Methods: For this purpose we did collect and summarize published data on pubmed using key words “Biologics, Rheumatoid Arthritis, Spondyloarthritis, Crohn disease, Anti drug antibodies, residual rate, immunogenicity, efficacy, tolerance”. The time-period selected for this study was 2000-2019.
Results: Anti- Drug-antibodies do decrease pharmaco-availability of drugs and in consequences its efficiency and high risk of refractory disease and side effects.
Conclusion: Recent literature is consistent with the fact that drug monitoring using ADA dosage coupled with residual drug concentration offers reliable options to comfort practitioner’ therapeutic management decisions. This is particularly interesting in failure to treatment or in side effects onset situations.
Anti drug antibodies, biologics, residual dose, spondyloarthritis, rheumatoid arthritis, crohn disease
Rheumatology Department, Military Hospital of Tunis, Rheumatology Department, Military Hospital of Tunis, Rheumatology Department, Military Hospital of Tunis, Rheumatology Department, Military Hospital of Tunis, Rheumatology Department, Military Hospital of Tunis, Internal Medicine Department, Military Hospital of Tunis